Financials
Financial year 2025
Gross margin
€ 1,993
▲ 140% vs 2024
Debts
Low€ 221,393
▲ 15190% vs 2024
JANSSEN - CILAG INTERNATIONAL from Beerse, company number BE0461607459, closed financial year 2025 with a result of € 0 after tax. For that financial year JANSSEN - CILAG INTERNATIONAL recorded a gross margin of € 1,993 and equity of € 165,897. Compared with financial year 2024, the result moved from € 0 to € 0. Around break-even. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2026.
What happened at JANSSEN - CILAG INTERNATIONAL?
What happened at JANSSEN - CILAG INTERNATIONAL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Laurence Oster-Gozet stepped down as director. NBB
- David Van Passel stepped down as director. NBB
- Margarita Gomez Chantraine stepped down as director. NBB
- Mark Peturson stepped down as director. NBB
- Filip Elens stepped down as director. NBB
- Alwin Otten stepped down as director. NBB
- Catherine Michielsens stepped down as director. NBB
- Elena Bolaños Cascales stepped down as director. NBB
In short
From € 0 profit in 2022 to € 0 profit in 2025.
A new publication or filing at JANSSEN - CILAG INTERNATIONAL? We notify you, reason included.
Follow JANSSEN - CILAG INTERNATIONALNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
The shares are held by Janssen Pharmaceutica NV (99%) and Johnson & Johnson (1%).
Directors
According to the 2025 annual accounts
Laurence Oster-Gozet
Director
since 2025 · until 2031
Elizabeth (Liz) Daly
Director
since 2024 · until 2025
Filip Elens
Director
since 2024 · until 2030
Alwin Otten
Director
since 2025 · until 2030
David Van Passel
Director
since 2025 · until 2031
Peter Willems
Chairman of the board
since 2023 · until 2029
Patrick Laroche
Director
since 2020 · until 2025
since 2022 · until 2025
Catherine Michielsens
Director
since 2024 · until 2030
Elena Bolaños Cascales
Director
since 2024 · until 2030
Margarita Gomez Chantraine
Director
since 2025 · until 2031
Mark Peturson
Director
since 2025 · until 2031
Shareholders
Johnson & Johnson
1%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Turnhoutseweg 30
2340 Beerse
Turnhoutsebaan 30
2340 Beerse
Active since 20 October 1997
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
Details
- Company number
- 0461.607.459
- VAT number
- BE 0461.607.459
- Registered office
- Turnhoutseweg 30, 2340 Beerse
- Names & denominations
- Johnson & Johnson, J&J, Johnson & Johnson Innovative Medicine, J&J Innovative Medicine · JANSSEN - CILAG INTERNATIONAL
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 6 October 1997
- Peppol
- Active · Active since 18 Dec 2025
- Activities · NACE
Overige zakelijke dienstverlening, neg